Predicting adverse outcomes in oncological nephrectomy: let's take a look at the patient around the tumor.
作者信息
Freitas Pedro F S, Vidal Rafael S R, Watanabe Carlos H, Arap Marco A
机构信息
Urologic Oncology Division, Hospital Sírio-Libanês, Brasília, DF, Brazil.
Urologic Oncology Division, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
出版信息
Transl Androl Urol. 2023 Jan 30;12(1):5-8. doi: 10.21037/tau-22-803. Epub 2023 Jan 9.
Abstract
摘要
相似文献
1
Predicting adverse outcomes in oncological nephrectomy: let's take a look at the patient around the tumor.预测肿瘤性肾切除术的不良结局：让我们关注肿瘤周围的患者情况。
Transl Androl Urol. 2023 Jan 30;12(1):5-8. doi: 10.21037/tau-22-803. Epub 2023 Jan 9.
2
Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy.形态组学可预测细胞减灭性肾切除术治疗转移性肾细胞癌的肿瘤学特征和生存情况。
Anticancer Res. 2021 Oct;41(10):5203-5211. doi: 10.21873/anticanres.15339.
3
Transperitoneal Robot-assisted Partial Nephrectomy with Minimum Follow-up of 5 Years: Oncological and Functional Outcomes from a Single Institution.经腹腔机器人辅助部分肾切除术：单中心 5 年以上随访的肿瘤学和功能结果。
Eur Urol Oncol. 2019 Mar;2(2):207-213. doi: 10.1016/j.euo.2018.06.012. Epub 2018 Jul 14.
4
Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4cm)? A propensity score-matched study.对于肾细胞癌（≥4cm）患者，与根治性肾切除术相比，部分肾切除术能否提供同等的肿瘤学疗效和安全性？一项倾向评分匹配研究。
Urol Oncol. 2017 Jun;35(6):379-385. doi: 10.1016/j.urolonc.2017.02.002. Epub 2017 Mar 9.
5
Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes.7cm 以上肾肿瘤行部分肾切除术：技术、肿瘤学和功能结局。
BJU Int. 2012 May;109(10):1450-6. doi: 10.1111/j.1464-410X.2011.10608.x. Epub 2012 Jan 5.
6
Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".部分肾切除术治疗肾细胞癌后癌症事件发生率低：1994 例病例的临床病理分析，重点是“复发”的定义。
Clin Genitourin Cancer. 2019 Jun;17(3):209-215.e1. doi: 10.1016/j.clgc.2019.03.004. Epub 2019 Mar 23.
7
The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer.腹腔镜肾切除术治疗 T3 期肾细胞癌的手术安全性和肿瘤学结果。
BJU Int. 2012 Sep;110(6):884-90. doi: 10.1111/j.1464-410X.2011.10850.x. Epub 2012 Jan 30.
8
Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy.肿瘤大小对根治性肾切除术治疗的病理T3aN0M0肾细胞癌肿瘤学结局的影响。
PLoS One. 2017 Mar 13;12(3):e0173953. doi: 10.1371/journal.pone.0173953. eCollection 2017.
9
Clinicopathological characteristics and oncological outcomes of patients with renal cell carcinoma.肾细胞癌患者的临床病理特征和肿瘤学结局。
Ceylon Med J. 2020 Sep 30;65(3):62-66. doi: 10.4038/cmj.v65i3.9187.
10
Comparative Outcome of Computed Tomography-guided Percutaneous Radiofrequency Ablation, Partial Nephrectomy or Radical Nephrectomy in the Treatment of Stage T1 Renal Cell Carcinoma.计算机断层扫描引导下经皮射频消融、部分肾切除术或根治性肾切除术治疗T1期肾细胞癌的比较结果
Rare Tumors. 2015 Mar 16;7(1):5583. doi: 10.4081/rt.2015.5583. eCollection 2015 Feb 11.
本文引用的文献
1
The association of body composition with postoperative complications and length of hospital stay after radical or partial nephrectomy in patients with renal cell cancer: a multicenter population-based cohort study.肾细胞癌患者行根治性或部分肾切除术后身体组成与术后并发症及住院时间的关联：一项基于多中心人群的队列研究
Transl Androl Urol. 2022 Dec;11(12):1667-1679. doi: 10.21037/tau-22-367.
2
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.欧洲泌尿外科学会肾癌指南：2022 年更新版。
Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.
3
Impact of Body Composition in Overweight and Obese Patients With Localised Renal Cell Carcinoma.超重和肥胖的局限性肾细胞癌患者的体成分的影响。
In Vivo. 2020 Sep-Oct;34(5):2873-2881. doi: 10.21873/invivo.12115.
4
The BMI Paradox and Robotic Assisted Partial Nephrectomy.体重指数悖论与机器人辅助部分肾切除术
Front Surg. 2020 Jan 9;6:74. doi: 10.3389/fsurg.2019.00074. eCollection 2019.
5
Obesity and 30-Day Outcomes Following Minimally Invasive Nephrectomy.微创肾切除术后的肥胖与30天预后
Urology. 2018 Nov;121:104-111. doi: 10.1016/j.urology.2018.08.002. Epub 2018 Aug 16.
6
Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis.身体成分与肾细胞癌临床结局的关系：系统评价和荟萃分析。
Eur Urol Focus. 2018 Apr;4(3):420-434. doi: 10.1016/j.euf.2016.11.009. Epub 2016 Dec 4.
7
Toward greater adoption of minimally invasive and nephron-sparing surgical techniques for renal cell cancer in the United States.在美国，推动肾细胞癌微创和保留肾单位手术技术的更广泛应用。
Urol Oncol. 2016 Oct;34(10):433.e9-433.e17. doi: 10.1016/j.urolonc.2016.05.021. Epub 2016 Jun 16.
8
Does Sarcopenia Impact Complications and Overall Survival in Patients Undergoing Radical Nephrectomy for Stage III and IV Kidney Cancer?肌肉减少症对接受 III 期和 IV 期肾癌根治性肾切除术患者的并发症及总生存期有影响吗？
J Endourol. 2016 Feb;30(2):229-36. doi: 10.1089/end.2015.0492. Epub 2015 Sep 29.
9
Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer.骨骼肌质量下降与局限性肾细胞癌根治性肾切除术后死亡风险增加相关。
J Urol. 2016 Feb;195(2):270-6. doi: 10.1016/j.juro.2015.08.072. Epub 2015 Aug 18.
10
Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.肌肉减少症作为转移性肾细胞癌减瘤性肾切除术后总生存期的预测指标。
Urol Oncol. 2015 Aug;33(8):339.e17-23. doi: 10.1016/j.urolonc.2015.01.011. Epub 2015 Jun 18.
Zotero 插件